4,5-Dioxo-4,5-dihydro-1H-pyrrolo[2,3-f]quinoline-7,9-dicarboxylic acid | 116451-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4,5-Dioxo-4,5-dihydro-1H-pyrrolo[2,3-f]quinoline-7,9-dicarboxylic acid
• 英文别名: 4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-7,9-dicarboxylic acid
• CAS: 116451-28-6
• 化学式: C₁₃H₆N₂O₆
• 分子量: 286.2
• InChiKey: IFYQITBEOBQUMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  137
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• LITHIUM DERIVATIVES OF PYRROLOQUINOLINE QUINONE AND PREPARATION METHOD THEREOF
  申请人：Zhong Chun-Jiu

  公开号：US20110313164A1

  公开（公告）日：2011-12-22

  Lithium derivatives of pyrroloquinoline quinone and preparation method thereof are disclosed. In said method, lithium derivatives of pyrroloquinoline quinone are obtained by an acid-base neutralization reaction in a basic solvent with pyrroloquinoline quinine (PQQ) as a starting material. Lithium ion is brought in the molecular structure of pyrroloquinoline quinone to form said lithium derivatives of pyrroloquinoline quinone. The reaction condition of said method is mild, the product is easy to be purified, the preparation procedure is simple, and the yield is more than 80%. Said lithium derivatives of pyrroloquinoline quinone possess GSK-3 inhibiting activity and possess the functions such as reducing the formation of age pigment in the brain of a transgenic mouse and reducing the phosphorylation of tau proteins. Said lithium derivatives of pyrroloquinoline quinone may be used in the manufacture of medicaments for preventing and treating senile dementia, senility or Parkinson's disease.

  本发明公开了吡咯喹啉喹啉醌的锂衍生物及其制备方法。在该方法中，以吡咯喹啉喹啉醌（PQQ）为起始物，在碱性溶剂中通过酸碱中和反应获得吡咯喹啉喹啉醌的锂衍生物。锂离子被引入吡咯喹啉喹啉醌的分子结构中，形成所述的锂衍生物。该方法的反应条件温和，产品易于纯化，制备过程简单，收率高达80%以上。所述的吡咯喹啉喹啉醌锂衍生物具有GSK-3抑制活性，具有降低转基因小鼠脑内老年斑形成和降低tau蛋白磷酸化等功能。所述的吡咯喹啉喹啉醌锂衍生物可用于制造预防和治疗老年性痴呆、衰老或帕金森病的药物。
• PYRROLOQUINOLINE QUINONE LITHIUM SALT CRYSTAL AND PREPARATION METHOD AND APPLICATION THEREOF
  申请人：SHANGHAI RI XIN BIOTECHNOLOGY CO., LTD.

  公开号：US20160137641A1

  公开（公告）日：2016-05-19

  The present invention provides pyrroloquinoline quinone lithium salt crystal and a preparation method and application thereof. Characteristic absorption peaks appear when the diffraction angles are 6.222±0.2°, 7.379±0.2°, 7.941±0.2°, 23.631±0.2°, 24.044±0.2°, 25.497±0.2°, 27.541±0.2°, 30.736±0.2°, and 32.306±0.2° degrees in a powder X-ray diffraction pattern of the pyrroloquinoline quinine lithium salt crystal. The maximum value of thermal absorption of the pyrroloquinoline quinine lithium salt crystal appears between 90° C. and 96° C. through differential scanning calorimetry. Peaks appear when infrared spectroscopy of the pyrroloquinoline quinine lithium salt crystal is at 3396.03 cm −1 , 1652.70 cm −1 , 1604.48 cm −1 , 1500.35 cm −1 , 1355.71 cm −1 , 1243.86 cm −1 , 1147.44 cm −1 , 808.03 cm −1 , 761.74 cm −1 , and 570.83 cm −1 . The pyrroloquinoline quinine lithium salt polymorphism can be applied to preparation of medicines for curing memory damage.
• US9738639B2
  申请人：——

  公开号：US9738639B2

  公开（公告）日：2017-08-22